|Animal efficacy studies done on the oral delivery of insulin using Transgene's
patented oral delivery technology, TrabiOral, have shown spectacular results
21st May 2012
Transgene announced today that recent animal efficacy studies done on the oral delivery of insulin using Transgene's patented oral delivery technology, TrabiOral, have shown spectacular results. Sustained optimal glycemic levels were demonstrated for approximately 10 hours following the oral dosage.
Transgene has signed an MOU with Armour Therapeutics of Canada, and a Term
Sheet with HealthPro BioVentures of New York
24th Apr 2012
Transgene has signed a Memorandum of Understanding with Armour Therapeutics of Canada to develop a novel delivery method for Armour's prostrate cancer molecule. Transgene has also signed a term sheet with New York based investment advisory firm HealthPro BioVentures. HealthPro will be exploring strategic opportunities for Transgene's pipeline.
Transgene Biotek has commenced commercial manufacturing operations of DHA,
an essential Omega-3 fatty acid
10th Oct 2011
Transgene Biotek today announced the commencement of commercial manufacturing operations of DHA, an Omega-3 fatty acid used as a nutraceutical product in health foods and supplements. GOED (Global Organization for EPA and DHA) currently values the Omega-3 market at US $18.6 billion (Rs. 90,000 Cr), and yet demand still outstrips supply.
Transgene Biotek is pleased to announce the placement
of GDRs to raise $23 million on the Luxembourg stock exchange
20th March 2011
We plan to utilise the proceeds to continue funding the development of our pipeline, construct an FDA compliant facility for the manufacture of API’s, expand growth via acquisitions, and to support the filing of a large number of new patents.
Transgene’s pipeline of projects consists of a host of ‘orphan’ drugs including molecules to treat Multiple myeloma and Multiple sclerosis, six anti-cancer molecules and a therapeutic vaccine to combat AIDS. Several of these molecules have reached the last stages of preclinical development and we now intend to begin filing INDA’s before the end of this year, after which we will likely begin to look towards partnering for one or two of these molecules.
Inorganic growth will become a key strategy for us going forward, something we believe will rapidly boost revenues, increase physical infrastructure, raise technology development expertise and skills, and also bring with it a list of key blue-chip clients who may in turn become ideal candidates for our molecule partnering program. Our acquisition search will extend into Europe and America which in turn will also give us a much awaited footprint into the Western markets.
One of Transgene’s strengths has been the maintenance of our Intellectual Property portfolio. The new capital raised will also be used towards the legal and regulatory expenses in filing new worldwide patents on our latest technology developments – something we believe will become the cornerstone of our value tomorrow.
Chinny Rao, Executive Director said “This GDR listing heralds a new era for Transgene. The point at which we are with our pipeline today, coupled with the Board’s new strategy to expand our presence abroad not only from the GDR listing but from what is now a strong desire to expand inorganically should set the tone for the future. We’re already in talks to begin that partnering search, and we’re already in the midst of a search for acquisition targets – so to me the future is bright, very bright in fact.
Transgene's monoclonal antibody drug demonstrates unique effect against three cancers
12th May, 2010
Transgene declared today that one
of its monoclonal antibodies (mAb), which was originally developed for
Colon Cancer, has demonstrated remarkable efficacy against two
additional cancers, namely Multiple Myeloma and Non-Hodgkin's Lymphoma.
So far, there is no other known monoclonal antibody drug in the world
that has demonstrated a similar therapeutic effect against all three
Transgene expands its Oncology pipeline with a novel drug for Colon Cancer
22nd Apr, 2010
Transgene has added a drug for
Colon Cancer that uses its Monoclonal Antibody technology platform to
its Oncology pipeline. Recent in-vitro studies have clearly established
its specificity, and have proved that it is an excellent cancer target
Transgene files 2 new patents on therapeutic AIDS vaccine and Multiple Sclerosis drug
22nd Mar, 2010
Two new patents have been filed by
Transgene for their proprietary autoimmune technology platform. The
first patent, for a therapeutic AIDS vaccine, was filed after it crossed
a significant milestone in proving its effectiveness. The second
patent, for a drug against the serious neurological disorder Multiple
Sclerosis, also employs Transgene's proprietary autoimmune technology
Transgene files 2 patents for Liver and Breast Cancer drugs
3rd Mar, 2010
Transgene has filed 2 patents for
its Liver and Breast Cancer drug technologies based on its proprietary
RNAi platform. Both patents follow excellent results in their respective
animal studies. Liver cancer is the 3rd most common cause of cancer
mortality, and breast cancer is the most common cancer in women. The
company is expecting to file more patents on some of its other
Transgene's novel drug against Breast Cancer provides encouraging results in animal studies
22nd Feb, 2010
A new drug for treating Breast
Cancer, developed using Transgene's proprietary RNAi technology
platform, has demonstrated exciting results in its latest animal
studies. This drug is specifically designed not only to treat primary
Breast Cancer but also to fight against potential metastatic tumours.
Worldwide, Breast Cancer is the most common cancer in women,
representing 16% of all female cancers, and causes well over 500,000
Transgene's novel Liver Cancer drug shows promise in latest animal studies
10th Feb, 2010
A novel drug for Liver Cancer
developed by Transgene Biotek's scientists has demonstrated excellent
efficacy in the latest animal studies, which corroborates earlier data
gathered from in-vitro studies. Transgene has employed its RNAi
platform, which utilizes a novel gene silencing technology, to develop
this drug, which has demonstrated remarkable regression of the tumours
in tests. Liver Cancer is the fifth most common cancer in the world, and
the third most common cause of cancer mortality.
Transgene's therapeutic AIDS Vaccine achieves critical milestone
25th Jan, 2010
Transgene Biotek has crossed a
significant milestone in demonstrating the efficacy of a therapeutic
AIDS vaccine developed by its scientists. This vaccine prevents the
progression of AIDS in HIV infected persons, and almost reverses the
AIDS process by enabling reactivation of the body's natural immunity,
which otherwise gets depleted and often results in death. The AIDS
vaccine is the first product to come out of a novel platform that
Transgene has built for drugs against auto-immune diseases. Other drugs
currently under development on this platform target Rheumatoid Arthritis
and Multiple Sclerosis, and the platform can be extended against other
autoimmune diseases such as Crohn's Disease etc.
(Business Standard) - Dr Reddy's: New molecule hopes
8th Jan, 2010
The second announcement of Dr
Reddy's is a tie-up with Indian biotechnology company Transgene Biotek
to manufacture and market Orlistat, an obesity management drug. The
market size for obesity management drugs accounts for $2 billion
worldwide with pancreatic lipase inhibitors such as Orlistat
contributing to about half of this.
Transgene Biotek Ltd signs Licensing and
Technology Transfer agreement with Dr. Reddy's Laboratories Ltd, Hyderabad
4th Jan 2010
Transgene Biotek (TBL) has entered
into a Licensing and Technology Transfer Agreement with Dr. Reddy's
Labs (DRL) for the outlicensing of a technology for the manufacture of
Orlistat, which was developed exclusively by TBL. This unique technology
will be licensed by TBL and manufactured and marketed by Dr. Reddy's
globally. The agreement should lead to substantial revenues being
generated for TBL and DRL for several years to come, and to a many fold
increase in TBL's bottomline. The market for Orlistat is estimated to be
around US $500 million per year.
|© 2011. TRANSGENE BIOTEK LIMITED.
||Designed by BitraNet